Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trastuzumab Deruxtecan With or Without Neratinib for HER2-positive Unresectable and/or Metastatic Breast Cancer With Brain Metastasis: A Multicenter, Randomized, Open Label, Phase II Trial (THUNDER Trial)

NCT07152782 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07152782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07152782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trastuzumab Deruxtecan With or Without Neratinib for HER2-positive Unresectable and/or Metastatic Breast Cancer With Brain Metastasis: A Multicenter, Randomized, Open Label, Phase II Trial (THUNDER Trial)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
September 24, 2025
Completion date
November 30, 2031
Enrollment
202 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer with brain metastasis, her2-positive breast cancer